rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions
Canavan Disease
Interventions
DRUG

rAAV-Olig001-ASPA

Intracerebroventricular administration of a single dose

DRUG

Levetiracetam

Keppra daily dose (20-50 mg/kg/day divided twice daily administered orally or per G-tube) in the post-operative period and continued for 3 months per standard of care to prevent seizure activity.

DRUG

Prednisone

Post-operatively, a 3-month steroid taper is planned to prevent or reduce possible delayed immunological responses. This tapering regimen will consist of 0.5 mg/kg/day prednisone during weeks 1-4; followed by 0.3 mg/kg/day prednisone during weeks 5-8; and 0.1mg prednisone during weeks 9-12, then off. If there is evidence of new inflammation on MRI at 3-months on T2 FLAIR, the steroid taper will be extended for an additional 3 months or we will transition to steroid-sparing immunosuppression.

Trial Locations (1)

45404

RECRUITING

Dayton Children's Hospital, Dayton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Myrtelle Inc.

INDUSTRY

NCT04833907 - rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease | Biotech Hunter | Biotech Hunter